Metabolic syndrome and risk of meningioma - population-based case-control analysis

Date of ISAC Approval: 
02/08/2016
Lay Summary: 
Metabolic syndrome (MetS) is a medical condition characterised by having at least 3 of the following 4 conditions: high blood pressure, insulin resistance (followed by high blood sugar levels), obesity (excess body fat around the waist) and high cholesterol levels. It affects around 15% of adult Europeans and has been increasing over the past years. Meningioma is a type of brain cancer that occurs in the cerebral meninges. One prior study found an increased risk of meningioma in patients suffering from metabolic syndrome, but further studies with larger sample sizes are needed to confirm those results. We therefore propose to conduct a study using the U.K.-based Clinical Practice Research Datalink (CPRD) to analyse the association between metabolic syndrome and the risk of meningioma.
Technical Summary: 
Using data from the CPRD, we intend to perform a matched case-control analysis to explore the association between metabolic syndrome and risk of meningioma. Cases will be individuals with an incident diagnosis of meningioma between 1995 and 2015. We will match ten control patients to each case on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the index date. Relative risks will be estimated by conducting conditional logistic regression analyses to determine odds ratios (ORs) with 95% confidence intervals (CIs) Analyses will be adjusted for various potential confounders.
Health Outcomes to be Measured: 
The association between metabolic syndrome and risk of meningioma
Collaborators: 

Christoph Meier - Chief Investigator - University of Basel
Claudia Becker - Researcher - University of Basel
Dr Corinna Seliger - Researcher - University of Regensburg
Professor Michael Leitzmann - Researcher - University of Regensburg
Professor Peter Hau - Researcher - University of Regensburg
Dr Susan S Jick - Researcher - BCDSP - Boston Collaborative Drug Surveillance Program
Ulrich Bogdahn - Researcher - University of Regensburg